Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Current Taxes (2020 - 2025)

Gain Therapeutics has reported Current Taxes over the past 6 years, most recently at $46289.0 for Q3 2025.

  • Quarterly results put Current Taxes at $46289.0 for Q3 2025, up 120.41% from a year ago — trailing twelve months through Sep 2025 was $46289.0 (up 120.41% YoY), and the annual figure for FY2024 was $18493.0, down 62.23%.
  • Current Taxes for Q3 2025 was $46289.0 at Gain Therapeutics, up from $25169.0 in the prior quarter.
  • Over the last five years, Current Taxes for GANX hit a ceiling of $184693.0 in Q2 2023 and a floor of $380.0 in Q4 2021.
  • Median Current Taxes over the past 5 years was $21001.0 (2024), compared with a mean of $43763.7.
  • Biggest five-year swings in Current Taxes: surged 28139.74% in 2022 and later tumbled 75.93% in 2025.
  • Gain Therapeutics' Current Taxes stood at $380.0 in 2021, then surged by 28139.74% to $107311.0 in 2022, then tumbled by 54.37% to $48965.0 in 2023, then plummeted by 62.23% to $18493.0 in 2024, then skyrocketed by 150.31% to $46289.0 in 2025.
  • The last three reported values for Current Taxes were $46289.0 (Q3 2025), $25169.0 (Q2 2025), and $17973.0 (Q1 2025) per Business Quant data.